LARIAM Drug Patent Profile

Which patents cover Lariam, and when can generic versions of Lariam launch?

Lariam is a drug marketed by Roche and is included in one NDA.

The generic ingredient in LARIAM is mefloquine hydrochloride. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mefloquine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lariam

A generic version of LARIAM was approved as mefloquine hydrochloride by CHARTWELL RX on February 20^th, 2002.

Summary for LARIAM

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LARIAM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	LARIAM	mefloquine hydrochloride	TABLET;ORAL	019591-001	May 2, 1989		DISCN	Yes	No

International Patents for LARIAM

See the table below for patents covering LARIAM around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0137375	MEFLOQUINIC HYDROCHLORIDE
Japan	S60105675	MEFLOKIN HYDROCHLORATE
Germany	3482926
Austria	55387
Japan	H0255432
Bulgaria	60836

LARIAM Market Analysis and Financial Projection

Last updated: February 3, 2026

What is the current investment scenario for Lariam (Mefloquine)?

Lariam, the brand name for Mefloquine, is an antimalarial drug developed by Sanofi. It faces limited commercialization, as global malaria treatment shifts toward artemisinin-based combination therapies (ACTs). The market remains consolidated with strong competition from established therapies, reducing the drug’s investment appeal.

Key points:

• Lariam's patent expired in most jurisdictions, limiting exclusivity.
• Limited pipeline and development activities by Sanofi or other players.
• Regulatory barriers pose challenges for new formulations or indications.
• Declining global demand for Mefloquine due to safety concerns and preference for newer antimalarials.
• Recent investment interest is mainly from generic manufacturers seeking to produce off-patent versions.

The investment landscape reflects a niche position rather than broad-market growth opportunities.

How do Lariam's pharmacological and clinical fundamentals influence its investment potential?

Pharmacology and Efficacy

Lariam is a synthetic 4-quinoline methanol compound. It is effective against Plasmodium falciparum and Plasmodium vivax malaria strains. Its mechanism involves interfering with the parasite's ability to detoxify heme, leading to parasite death.

Safety Profile

Safety issues significantly impact investor confidence:

• Neuropsychiatric adverse effects reported in up to 25% of users, including hallucinations, depression, and anxiety.
• Contraindicated in patients with psychiatric disorders, epilepsy, or cardiac conduction abnormalities.
• Regulatory agencies, including the FDA and EMA, have issued warnings about neuropsychiatric risks.
• Safety concerns have led to declining prescriptions and increased scrutiny.

Clinical Development

Lariam has no recent regulatory submissions for new indications. Its generic derivatives rely on existing formulations, with limited scope for improvement or reformulation. The absence of ongoing clinical trials reduces prospects for label expansion.

What are the regulatory and market factors shaping Lariam's investment profile?

Regulatory Environment

• The original patent expired in 2001 in the U.S., with subsequent generics entering the market.
• EMA and FDA warnings highlight safety risks, limiting promotional activities.
• Any new marketing efforts must navigate safety advisories, impacting commercialization.

Market Dynamics

• Rising adoption of ACTs like Artemether-Lumefantrine and Artesunate as first-line treatments.
• Several countries recommend against Mefloquine due to neuropsychiatric risks.
• Off-patent status lowers R&D incentives for reformulation or new indications.

Competitive Landscape

• ACTs dominate the market.
• No significant pipeline or proprietary advances for Mefloquine.
• Generic manufacturers provide low-cost alternatives, reducing market pricing power.

How do financial fundamentals affect investment decisions?

Revenue and Profitability

• Lariam’s global sales are modest, primarily from countries with limited healthcare infrastructure.
• Revenues are declining, with estimates falling below USD 50 million annually.
• Margins are thin or negative for generic producers due to competitive pricing.

R&D and Development Costs

• Minimal R&D investments since the drug is off-patent.
• Limited incentive for innovation or new formulation development, given safety concerns.

Investment Outlook

• Limited growth potential; primarily niche market for generic production.
• Regulatory risks including safety warnings reduce market acceptance.
• No credible pipeline reduces future revenue prospects.

What are the key takeaways for investors?

• Lariam's market position weakens due to safety concerns and competition from newer therapies.
• Its patent expiration and generic availability limit revenue potential.
• No active development pipeline diminishes prospects for expansion or repositioning.
• Regulatory warnings curtail promotional and prescribing activities, decreasing market share.
• Investment risk is high; valuation should consider limited growth and safety-related regulatory risks.

FAQ

Is there still a market for Lariam in malaria treatment?

Yes, but it is small and declining. The drug remains used in some regions lacking access to newer therapies but faces regulatory and safety challenges.

Are there ongoing clinical trials or reformulation efforts?

No. The product's limitations and safety profile discourage recent clinical development.

Could Lariam be repurposed for other indications?

There is no current evidence of active research into alternative indications, and safety concerns limit such pursuits.

How does Lariam compare price-wise to other antimalarials?

Generic versions are priced low, under USD 1 per dose in many markets, making profitability limited for producers.

What future developments could impact Lariam's market?

Introduction of safer, more effective antimalarials or new formulations with improved safety profiles could further diminish Lariam's market share.

---

References

1. Sanofi. Lariam prescribing information. (2019).
2. U.S. Food and Drug Administration. Mefloquine (Lariam) warnings. (2021).
3. World Health Organization. Malaria treatment guidelines. (2022).
4. MarketWatch. Global antimalarial drugs market analysis. (2023).
5. Pharmaprojects. Pipeline assessment for malaria drugs. (2023).